Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may
help doctors learn more about changes that occur in DNA and identify biomarkers related to
cancer. It may also help doctors predict how patients will respond to treatment with
erlotinib.
PURPOSE: This clinical trial is studying how well erlotinib works when given before surgery
in treating patients with head and neck cancer that can be removed by surgery.
Phase:
Early Phase 1
Details
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University Wake Forest University Health Sciences